ZOM's Business Model
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.zomedica.com |
| CEO (Chief Executive Officer) | Larry C. Heaton II |
| Number of Employees | |
| IPO date | November 21, 2017 |
ZOM Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 100 Phoenix Drive |
| City | Ann Arbor |
| State | MI |
| Phone | 734 369 2555 |
| Zip Code | 48108 |
| Other Identifiers | |
| CIK | 0001684144 |
| ISIN | CA98980M1095 |
| CUSIP | 98980M109 |
| Open | 0.092 |
| Previous Close | 0.0975 |
| Volume | 790.9 Thou. |
| Average Volume | 8.54 Mil. |
| Day’s Range | 0.092 – 0.0973 |
| 52 Week Range | 0.0151-0.1952 |
| MA (50) | 0.11441 |
| MA (200) | 0.12976 |
| Market Cap | 95.35 Mil. |
| Shares Out. | 980 Mil. |
| Earnings Date | Mar 13, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
